Get started
Author

Di Zhou

ORCID: 0000-0002-2398-8408
Observed ORCID: 0000-0002-2398-8408
OpenAlex ID: A5049335113
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
2023 · Di Zhou, Lauren A. Byers, et al. · The Journal of Clinical Pharmacology · 51
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
2023 · Ana Ruiz-Garcia, Paul Baverel, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 51
PDF
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
2022 · Johannes Kast, Saeideh Nozohouri, et al. · Clinical and Translational Science · 23
PDF
The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects
2026 · Jiaqi Lu, Jing Cui, et al. · Signal Transduction and Targeted Therapy · 5
PDF
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
2025 · Cesar Rodriguez, Tulio Rodriguez, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
PDF
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma
2026 · Hans C. Lee, Wouter J. Plattel, et al. · Blood · 3
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
2024 · Di Zhou, Roman Kischel, et al. · Clinical Pharmacology & Therapeutics · 3
Optimizing Clinical Dosing Strategies to Mitigate Corneal Toxicity: Ocular PBPK Model-Based Evaluation of the Extent and Rate of Therapeutic Protein Distribution in the Human Cornea
2024 · Annie Lumen, Leticia Arrington, et al.
Works count: 8
Citation count: 140
H-index: 4
I10-index: 3
Year
Topic
Type